Akèy › Lukemi lenfositè kwonik › Rhode Island › Providence

Etid klinik pou Lukemi lenfositè kwonik nan Providence, RI

5 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan ak bò kote Providence (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Ap rekriteFaz 3

Rhode Island Hospital, Providence

Laj 65 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07321652

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Ap rekriteFaz 1/2

Research Site, Providence

Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06564038

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Ap rekriteFaz 1

Lifespan Cancer Institute at Rhode Island Hospital, Providence

Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT03666000

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Ap rekriteFaz 3

Lifespan Cancer Institute - Providence /ID# 266550, Providence

Laj 18 ak plis · Tout sèks · Mizajou Apr 9, 2026 · NCT06428019

Study of SGR-1505 in Mature B-Cell Neoplasms

Ap rekriteFaz 1

Rhode Island Hospital, Providence

Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT05544019

Etid Lukemi lenfositè kwonik nan lòt vil

Lòt etid nan Providence

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.